Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 2
1998 4
1999 2
2000 1
2001 3
2003 3
2004 2
2005 2
2006 4
2007 8
2008 5
2009 6
2010 5
2011 11
2012 8
2013 7
2014 6
2015 10
2016 5
2017 7
2018 9
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 15479440

113 results
Results by year
Filters applied: . Clear all
Page 1
Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.
Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, Pichardo D, Urquiza D, Rodríguez D, Silva D, Petrovsky N, Guillén G. Aguilar JC, et al. Immunol Cell Biol. 2004 Oct;82(5):539-46. doi: 10.1111/j.0818-9641.2004.01278.x. Immunol Cell Biol. 2004. PMID: 15479440
Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX. Li J, et al. Vaccine. 2015 Aug 20;33(35):4247-54. doi: 10.1016/j.vaccine.2015.03.079. Epub 2015 Apr 6. Vaccine. 2015. PMID: 25858855
Nasal route favors the induction of CD4+ T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine.
Bourgine M, Crabe S, Lobaina Y, Guillen G, Aguilar JC, Michel ML. Bourgine M, et al. Antiviral Res. 2018 May;153:23-32. doi: 10.1016/j.antiviral.2018.02.019. Epub 2018 Mar 3. Antiviral Res. 2018. PMID: 29510155
Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M. Akbar SM, et al. Antiviral Res. 2012 Oct;96(1):59-64. doi: 10.1016/j.antiviral.2012.07.011. Epub 2012 Aug 1. Antiviral Res. 2012. PMID: 22884884
Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S, Qiu L, Liu G, Li Y, Zhang X, Jin W, Gao GF, Kong X, Meng S. Wang S, et al. Vaccine. 2011 Aug 26;29(37):6342-51. doi: 10.1016/j.vaccine.2011.05.008. Epub 2011 May 19. Vaccine. 2011. PMID: 21600951
Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model.
Mahdavi M, Mavandadnejad F, Yazdi MH, Faghfuri E, Hashemi H, Homayouni-Oreh S, Farhoudi R, Shahverdi AR. Mahdavi M, et al. J Infect Public Health. 2017 Jan-Feb;10(1):102-109. doi: 10.1016/j.jiph.2016.02.006. Epub 2016 Mar 23. J Infect Public Health. 2017. PMID: 27026241 Free article.
Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.
Obeng-Adjei N, Choo DK, Saini J, Yan J, Pankhong P, Parikh A, Chu JS, Weiner DB. Obeng-Adjei N, et al. Cancer Gene Ther. 2012 Nov;19(11):779-87. doi: 10.1038/cgt.2012.61. Epub 2012 Oct 5. Cancer Gene Ther. 2012. PMID: 23037809 Free PMC article.
Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
Chen X, Li M, Le X, Ma W, Zhou B. Chen X, et al. Vaccine. 2004 Jan 2;22(3-4):439-46. doi: 10.1016/j.vaccine.2003.07.014. Vaccine. 2004. PMID: 14670326
Comparative study of the immunogenicity and immunoenhancing effects of two hepatitis B core antigen variants in mice by nasal administration.
Lobaina Y, Palenzuela D, García D, Rodríguez D, Pichardo D, Muzio V, Aguilar JC. Lobaina Y, et al. Vaccine. 2006 Apr 12;24 Suppl 2:S2-58-9. doi: 10.1016/j.vaccine.2005.01.122. Vaccine. 2006. PMID: 16823928
Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, Tang Z. Dai S, et al. Immunobiology. 2016 Jul;221(7):813-21. doi: 10.1016/j.imbio.2016.01.015. Epub 2016 Feb 2. Immunobiology. 2016. PMID: 26874581
113 results
Jump to page
Feedback